<DOC>
	<DOCNO>NCT00344760</DOCNO>
	<brief_summary>We hypothesize use potent antiretroviral Enfuvirtide induction phase HAART therapy lead faster clearance virus infect cell , low number minority variant HIV-1 strain .</brief_summary>
	<brief_title>A Study Evaluate Efficacy Enfuvirtide During Induction Phase Therapy</brief_title>
	<detailed_description>This 48 week Phase 4 , open label , randomize , prospective , pilot proof concept study evaluate use Enfuvirtide induction/maintenance treatment model . Patients meet inclusion criterion stratify two group accord HIV-1 RNA viral load ( less 300,000 copies/ml great 300,000 copies/ml ) . Thereafter , patient block randomize ( size block two patient ) one two treatment arm . All patient receive Efavirenz 600mg day , Lamivudine 300 mg day , Tenofovir 300mg day . After randomization , one half patient receive additional treatment , half receive Enfuvirtide 90mg sq BID viral load &lt; 50 x 2 consecutive visit 12 week ( whichever come first ) .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Efavirenz</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<mesh_term>Enfuvirtide</mesh_term>
	<criteria>1 . Age : 18 70 year age . 2 . Sex : Male Female . 3 . Documented HIV1 seropositive Western Blot , Elisa , HIV1 viral load . 4 . Na√Øve HAART . 5 . Viral load &gt; 100,000c/ml . 6 . CD4 &lt; 200c/ml . 7 . Volunteers must willing able provide write informed consent participate study . 8 . Available least 48 week followup . 1 . Volunteers acute clinically significant medical event determine investigator result life expectancy le 12 month despite ART . 2 . Volunteers current psychiatric illness , alcohol abuse illicit drug use opinion Principal Investigator may interfere patient 's ability comply protocol requirement . 3 . Renal insufficiency ( Estimated Creatinine clearance &lt; 60ml/min . ) 4 . Patients malabsorption severe chronic diarrhea 30 day . 5 . Inability consume adequate oral intake ( defined inability eat least 1 meal per day ) . 6 . Current treatment malignancy basal squamous cell carcinoma skin carcinoma situ cervix . 7 . Any medical condition , opinion investigator , might interfere completion study evaluation result . 8 . Pregnancy breastfeed 9 . In female capable child bearing , unwillingness use effective barrier contraception abstinence 10 . Patient currently receive experimental medication .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2013</verification_date>
</DOC>